MoonLake Immunotherapeutics
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
| MOONLAKE IMMUNOTHERAPEUTICS | |||
| /s/ Dr. Jorge Santos da Silva | |||
| Date: | February 25, 2026 | Name: | Dr. Jorge Santos da Silva |
|---|---|---|---|
| Title: | Chief Executive Officer | ||
| (Principal Executive Officer) | |||
| /s/ Matthias Bodenstedt | |||
| Date: | February 25, 2026 | Name: | Matthias Bodenstedt |
| Title: | Chief Financial Officer | ||
| (Principal Financial and Accounting Officer) | |||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dr. Jorge Santos da Silva and Matthias Bodenstedt, and each of them, the true and lawful attorneys-in-fact and agents of the undersigned, with full power of substitution and resubstitution, for and in the name, place and stead of the undersigned, to sign in any and all capacities (including, without limitation, the capacities listed below), this Annual Report on Form 10-K, any and all amendments thereto, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and anything necessary to be done to enable the registrant to comply with the provisions of the Securities Exchange Act and all the requirements of the Securities and Exchange Commission, as fully to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute, or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Dr. Jorge Santos da Silva | Chief Executive Officer; Director | February 25, 2026 |
| Dr. Jorge Santos da Silva | (Principal Executive Officer) | |
| /s/ Matthias Bodenstedt | Chief Financial Officer | February 25, 2026 |
| Matthias Bodenstedt | (Principal Financial and Accounting Officer) | |
| /s/ Simon Sturge | Chairperson; Director | February 25, 2026 |
| Simon Sturge | ||
SIGNATURES
| /s/ Spike Loy | Director | February 25, 2026 |
|---|---|---|
| Spike Loy | ||
| /s/ Catherine Moukheibir | Director | February 25, 2026 |
| Catherine Moukheibir | ||
| /s/ Dr. Andrew Phillips | Director | February 25, 2026 |
| Dr. Andrew Phillips | ||
| /s/ Dr. Ramnik Xavier | Director | February 25, 2026 |
| Dr. Ramnik Xavier | ||
INDEX TO FINANCIAL STATEMENTS
| Page | ||
| Report of Independent Registered Public Accounting Firm (Baker Tilly US, LLP - PCAOB Firm ID No. 23) | F-2 | |
|---|---|---|
| Consolidated Balance Sheets | F-4 | |
| Consolidated Statements of Operations and Comprehensive Loss | F-5 | |
| Consolidated Statements of Changes in Equity | F-6 | |
| Consolidated Statements of Cash Flows | F-9 | |
| Notes to Consolidated Financial Statements | F-10 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.